A for augmented: Cambridge AI company out to capture biomedical knowledge gets $60M from Mayo, Silicon Valley VC

Amber Tong

Senior Editor

The Mayo Clinic is joining hands with a Silicon Valley VC firm to inject $60 million into nference, a Cambridge, MA-based player in the gold rush to capitalize on biopharma’s growing interest — and urge — to accelerate drug discovery and development using the latest machine learning tools.

While nference ostensibly belongs to a generation of software startups that cropped up around 2013, it doesn’t see itself as part of the AI mainstream, founder and CSO Venky Soundararajan tells Endpoints News. That’s why the A in their AI stands for augmented, not artificial.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

A for augmented: Cambridge AI company out to capture biomedical knowledge gets $60M from Mayo, Silicon Valley VC

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir

A for aug­ment­ed: Cam­bridge AI com­pa­ny out to cap­ture bio­med­ical knowl­edge gets $60M from Mayo, Sil­i­con Val­ley VC

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Sen­a­tors want to know more on why No­vo is dis­con­tin­u­ing its in­sulin Lev­emir

A for augmented: Cambridge AI company out to capture biomedical knowledge gets $60M from Mayo, Silicon Valley VC

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir